Charles Schoch - 12 Jan 2024 Form 3 Insider Report for Candel Therapeutics, Inc. (CADL)

Role
Interim Chief Financial Officer; Exhibit 24 - Power of Attorney
Signature
/s/ Charles Schoch
Issuer symbol
CADL
Transactions as of
12 Jan 2024
Net transactions value
$0
Form type
3
Filing time
19 Jan 2024, 08:30:23 UTC
Next filing
15 Jul 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding CADL Common Stock 2,000 12 Jan 2024 Direct
holding CADL Common Stock 79,301 12 Jan 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding CADL Stock Option (Right to Buy) 12 Jan 2024 Common Stock 25,000 $10.36 Direct F2
holding CADL Stock Option (Right to Buy) 12 Jan 2024 Common Stock 39,498 $1.29 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock upon vesting and settlement. 50% of the RSUs shall vest on June 30, 2024, and the remaining 50% on December 31, 2024, in each case subject to the Reporting Person's continued service on such vesting date.
F2 25% of the shares underlying this option shall vest and become exercisable on November 16, 2022, with the remainder vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.
F3 The shares underlying this option shall vest and become exercisable in forty-eight (48) equal monthly installments following April 28, 2023, subject to the Reporting Person's continued service on each such vesting date.

Remarks:

Interim Chief Financial Officer; Exhibit 24 - Power of Attorney